Lymphocytes, Interleukin 6 and D-dimer Cannot Predict Clinical Outcome in Coronavirus Cancer Patients: LyNC1.20 Study.

Vanni, Gianluca; Materazzo, Marco; Dauri, Mario; Farinaccio, Andrea; Buonomo, Chiara; Portarena, Ilaria; Pellicciaro, Marco; Legramante, Jacopo Maria; Rizza, Stefano; Chiaramonte, Carlo; Bellia, Alfonso; Grande, Michele; Potenza, Saverio; Sbordone, Francesco Paolo; Perrone, Marco Alfonso; Grimaldi, Francesco; Chiocchi, Marcello; Buonomo, Oreste Claudio

BACKGROUND/AIM Knowledge of Coronavirus 19 (COVID19) pathogenetic mechanisms is necessary to provide new treatment strategies. This study aims to assess how oncological disease impacts on the clinical course of COVID-19 patients. PATIENTS AND METHODS From 1st March to 30th April 2020, 96 COVID-19 patients were classified according to clinical outcome as severe (n=67) and moderate (n=29). Demographic data, medical history, admission lymphocytes, procalcitonin (PCT), c-reactive-protein (CRP), D-dimer, and Interleukin-6 (IL-6) were collected. RESULTS A statistically significant association was found between hypertension (p=0.007) and three or more comorbidities with severe outcomes (p=0.034). No statistical differences were found between the severe and moderate groups with regards to the rate of patients with past oncological history. However, no patient allocated in the moderate group had received oncological treatment within 12 months. Higher values of CRP, IL-6, D-Dimer and lower values of lymphocytes were reported in the severe group (p=0.0007, p=0.00386, p=0.041, and p=0.007, respectively). Using binary logistic regression, higher values of CRP (OR=8.861; p=0.012) and PCT were associated with a higher risk of severe outcome (OR=21.075; p=0.008). Within the oncological population, D-Dimer and IL-6 did not confirm their prognostic significance as in the general population (p>0.05). CONCLUSION Specific prognostic factors for oncological patients should be designed for COVID-19 clinical practice.